High-dose-rate brachytherapy boost to the dominant intra-prostatic tumor region: Hemi-irradiation of prostate cancer

Prostate

Volumn 71, Issue 12, 2011, Pages 1309-1316

  Schick, Ulrike ^a   Popowski, Youri ^a   Nouet, Philippe ^a   Bieri, Sabine ^b   Rouzaud, Michel ^a   Khan, Haleem ^c   Weber, Damien Charles ^a   Miralbell, Raymond ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Hopital de Sion   (Switzerland)

^c Institute of Radiology Jean Violette   (Switzerland)

Author keywords

brachytherapy; high dose rate; prostate cancer; toxicity; unilateral lobe involvement

Indexed keywords

BICALUTAMIDE; GOSERELIN; IRIDIUM 192;

ACUTE LOW GASTROINTESTINAL TOXICITY; ACUTE TOXICITY; ACUTE URINARY TOXICITY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CYSTECTOMY; DISEASE FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH DOSE RATE BRACHYTHERAPY; HUMAN; INTESTINE EXAMINATION; MAJOR CLINICAL STUDY; MALE; MALE GENITAL SYSTEM DISEASE; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECTOVESICAL FISTULA; RECTUM FISTULA; THREE DIMENSIONAL CONFORMAL EXTERNAL RADIOTHERAPY; TREATMENT FAILURE;

AGED; BRACHYTHERAPY; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE; UROGENITAL SYSTEM;

EID: 79960708736     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21347     Document Type: Article

References (27)

1. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ,. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007; 110 (4): 906-910. (Pubitemid 47257670)
2. Tsivian M, Kimura M, Sun L, Mouraviev V, Mayes JM, Polascik TJ,. Predicting unilateral prostate cancer on routine diagnostic biopsy: Sextant vs extended. BJU Int 2010; 105 (8): 1089-1092.
3. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM,. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 2004; 171 (3): 1089-1092. (Pubitemid 38327533)
4. Coakley FV, Kurhanewicz J, Lu Y, Jones KD, Swanson MG, Chang SD, Carroll PR, Hricak H,. Prostate cancer tumor volume: Measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002; 223 (1): 91-97. (Pubitemid 34258194)
5. Hricak H,. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol 2005; 78 (Spec No 2): S103-S111. (Pubitemid 43019918)
6. Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J, Mueller-Lisse U, Carroll PR, Kurhanewicz J,. Sextant localization of prostate cancer: Comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164 (2): 400-404. (Pubitemid 30481935)
7. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, Cservenyak T, Hany TF,. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35 (2): 253-263.
8. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, Nader M, Gruy B, Janetschek G, Langsteger W,. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: A prospective study of 130 patients. Radiology 2010; 254 (3): 925-933.
9. Bahn DK, Silverman P, Lee F, Sr., Badalament R, Bahn ED, Rewcastle JC,. Focal prostate cryoablation: Initial results show cancer control and potency preservation. J Endourol 2006; 20 (9): 688-692. (Pubitemid 46140997)
10. Aus G,. Current status of HIFU and cryotherapy in prostate cancerA review. Eur Urol 2006; 50 (5): 927-934; discussion 934. (Pubitemid 44486493)
11. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J,. " Male lumpectomy:" Focal therapy for prostate cancer using cryoablation. Urology 2007; 70 (6 Suppl): 16-21.
12. Shelley M, Wilt TJ, Coles B, Mason MD,. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev 2007; (3): CD005010.
13. Galalae RM, Kovacs G, Schultze J, Loch T, Rzehak P, Wilhelm R, Bertermann H, Buschbeck B, Kohr P, Kimmig B,. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002; 52 (1): 81-90. (Pubitemid 34044108)
14. Martin T, Roddiger S, Kurek R, Dannenberg T, Eckart O, Kolotas C, Heyd R, Rogge B, Baltas D, Tunn U, Zamboglou N,. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol 2004; 71 (1): 35-41. (Pubitemid 38452900)
15. Roach M III, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, Navvab Z, Carroll PR,. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28 (1): 33-37. (Pubitemid 24012852)
16. Ares C, Popowski Y, Pampallona S, Nouet P, Dipasquale G, Bieri S, Ozsoy O, Rouzaud M, Khan H, Miralbell R,. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: A sequential dose-escalation pilot study. Int J Radiat Oncol Biol Phys 2009; 75 (3): 656-663.
17. Cox JD, Stetz J, Pajak TF,. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31 (5): 1341-1346.
18. Roach M III, Hanks G, Thames H, Jr., Schellhammer P, Shipley WU, Sokol GH, Sandler H,. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65 (4): 965-974.
19. Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G,. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005; 61 (5): 1306-1316. (Pubitemid 40470411)
20. Duchesne GM, Williams SG, Das R, Tai KH,. Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: Mature prospective phase I/II study results. Radiother Oncol 2007; 84 (2): 128-134. (Pubitemid 47284528)
21. Astrom L, Pedersen D, Mercke C, Holmang S, Johansson KA,. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 2005; 74 (2): 157-161. (Pubitemid 40331872)
22. Hoskin P,. High dose rate brachytherapy for prostate cancer. Cancer Radiother 2008; 12 (6-7): 512-514.
23. Ghilezan M, Vargas C, Gustafson G,. Chronic toxicity profile and biochemical outcome in favorable-stage prostate cancer patients undergoing monotherapy with HDR and LDR (Pd103) brachytherapy at William Beaumont Hospital. Radiother Oncol 2004; 71 (Suppl 2): S52.
24. Charra-Brunaud C, Hsu IC, Weinberg V, Pouliot J,. Analysis of interaction between number of implant catheters and dose-volume histograms in prostate high-dose-rate brachytherapy using a computer model. Int J Radiat Oncol Biol Phys 2003; 56 (2): 586-591. (Pubitemid 36542918)
25. Isbarn H, Karakiewicz PI, Vogel S, Jeldres C, Lughezzani G, Briganti A, Montorsi F, Perrotte P, Ahyai SA, Budaus L, Eichelberg C, Heuer R, Kollermann J, Sauter G, Schlomm T, Steuber T, Haese A, Zacharias M, Fisch M, Heinzer H, Huland H, Chun FK, Graefen M,. Unilateral prostate cancer cannot be accurately predicted in low-risk patients. Int J Radiat Oncol Biol Phys 2010; 77 (3): 784-787.
26. Onik G, Miessau M, Bostwick DG,. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009; 27 (26): 4321-4326.
27. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT,. Imaging prostate cancer: A multidisciplinary perspective. Radiology 2007; 243 (1): 28-53. (Pubitemid 46579693)